Omnix Medical’s agents are based on natural antimicrobial peptides, genetically engineered to be compatible for therapeutic use. Omnix peptides target severe Hospital Acquired Infections (HAI) involving Multidrug Resistant (MDR) bacteria and are highly effective against a wide spectrum of bacteria species. Presently, Omnix is focusing on Priority Pathogens as designated by WHO/CDC, namely, the Gram-negative ESKAPE pathogens:
K. pneumonia, A. baumannii, P. aeruginosa and Enterobacter species. While these bacteria are the most serious and urgent threat to public health, the drugs intended to fight them are becoming ineffective as they rapidly develop resistance even to our last line of defense antibiotic treatments.

Omnix peptides are being developed for systemic Intravenous (IV) administration in serious or life-threatening Hospital Associated Infections.

Omnix is addressing an enormous and rapidly growing market opportunity, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Experts estimate that by the year 2050, drug-resistant bacteria will cause more than 10 million deaths every year and cost the global economy an excess of $100 trillion annually.

Omnix Medical’s agents are eligible for a Qualified Infectious Disease Product (QIDP) Designation which is granted by the FDA. QIDP status allows for a fast-track route through the regulatory/development pathway and an additional five years of marketing exclusivity.

Omnix Medical FCOI Policy

Research Misconduct Person In Charge: Ms. Shira Mandel, VP Research and Discovery